Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/- Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone

被引：7

作者：

Boehrer, Simone ^{[1
]}

Beyne-Rauzy, Odile ^{[2
]}

Prebet, Thomas ^{[3
]}

Park, Sophie ^{[4
]}

Guerci, Agnes ^{[5
]}

Stamatoulas, Aspasia ^{[6
]}

Chaury, M. P. ^{[7
]}

Jernival, Tony ^{[1
]}

Sanhes, Laurence ^{[8
]}

Tertian, Gerard ^{[9
]}

Cheze, Stephane ^{[10
]}

Lim, Eng-Mong ^{[11
]}

Choufi, Bachra ^{[12
]}

Caillot, Denis ^{[13
]}

Wattel, E. ^{[14
]}

Delaunay, Jacques ^{[15
]}

Legros, Laurence ^{[16
]}

Chermat, Fatiha ^{[17
]}

Isnard, Francoise ^{[18
]}

Cambier, N. ^{[19
]}

Slama, Borhane ^{[20
]}

Roy, Lydia ^{[21
]}

Damaj, Gandhi ^{[22
]}

Raffoux, Emmanuel ^{[23
]}

Dreyfus, Francois ^{[24
]}

Recher, Christian ^{[25
]}

Vey, Norbert ^{[26
]}

Chevret, Sylvie ^{[23
]}

Fenaux, Pierre ^{[27
]}

Gardin, Claude ^{[11
]}

机构：

[1] Univ Paris 13, Hop Avicenne, APHP, Bobigny, France

[2] Hop Purpan, Toulouse, France

[3] Inst J Paoli I Calmettes, Dept Hematol, F-13009 Marseille, France

[4] Univ Paris 05, Hop Cochin, Serv Hematol, Paris, France

[5] CHU Nancy, Nancy, France

[6] Ctr Henri Becquerel, Dept Hematol, F-76038 Rouen, France

[7] CHRU Limoges, Limoges, France

[8] Hop Hotel Dieu, INSERM, E0355, Paris, France

[9] Hop Bicetre, Caen, France

[10] CHU Clemenceau, Serv Hematol Clin, Caen, France

[11] Hop Avicenne, Serv Hematol Clin, F-93009 Bobigny, France

[12] Ctr Hosp Boulogne Mer, Boulogne, France

[13] CHU, Dijon, France

[14] Ctr Hosp Edouard Herriot, Lyon, France

[15] CHU Nantes, Dept Hematol, F-44035 Nantes 01, France

[16] Hop Archet, Serv Hematol, Nice, France

[17] GFM, Bobigny, France

[18] St Antoine Hosp, Paris, France

[19] Hop St Vincent de Paul, Lille, France

[20] CH Avignon, Avignon, France

[21] Univ Poitiers Hosp, Poitiers, France

[22] Univ Hosp CHU Sud, Amiens, France

[23] Hop St Louis, Paris, France

[24] Univ Paris 05, INSERM, Fac Med Rene Descartes, CNRS,U1016,UMR 8104,UM 3,Cochin Inst,Hematol Dept, F-75270 Paris, France

[25] CHU Purpan, Serv Hematol Clin, Toulouse, France

[26] Hop Paoli Calmettes, Marseille, France

[27] Univ Paris 13, Hop Avicenne, Serv Hematol Clin, Bobigny, France

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

10.1182/blood.V116.21.1880.1880

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：784 / 784

页数：1

共 50 条

[21] Alrizomadlin (APG-115) Alone or Combined with Azacitidine (AZA) in Patients (pts) with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Relapsed or Progressive Higher-Risk Myelodysplastic Syndrome (HR-MDS): Phase 1b Trial Results
Qi, Junyuan
Wei, Xudong
Li, Qiubai
Chang, Chukang
Zhou, Fuling
Huang, Jianying
Zhang, Yu
Xu, Chongyuan
Tang, Xiaowen
Jiang, Qian
Li, Junmin
Qin, Qun
He, Qun
Gao, Sujun
Liu, Liping
Chen, Zi
Yu, Min
Wang, Jing
Men, Lichuang
Wang, Hengbang
Ahmad, Mohammad
Yang, Dajun
Zhai, Yifan
Wang, Jianxiang
BLOOD, 2023, 142
[22] A Phase II Study of Valproic Acid and Lenalidomide Combination Therapy in Patients with Myelodysplastic Syndrome (MDS) and a Favorable Risk Profile: Final Results of the Valena Trial
Kuendgen, Andrea
Luebert, Michael
Schlenk, Richard F.
Platzbecker, Uwe
Haase, Detlef
Haferlach, Torsten
Schnittger, Susanne
Giagounidis, Aristoteles
Brings, Carolin
Germing, Ulrich
Haas, Rainer
Gattermann, Norbert
BLOOD, 2014, 124 (21)
[23] Long-Term Evaluation of Luspatercept in Erythropoiesis-Stimulating Agent (ESA)Intolerant/Refractory Patients (pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS) in the Phase 3 MEDALIST Study
Santini, Valeria
Komrokji, Rami S.
Garcia-Manero, Guillermo
Buckstein, Rena
Oliva, Esther Natalie
Keeperman, Karen L.
Rose, Shelonitda
Giuseppi, Ana Carolina
Vilmont, Valerie
Lai, Yinzhi
Miteva, Dimana
Aggarwal, Barkha
Platzbecker, Uwe
Fenaux, Pierre
Zeidan, Amer M.
BLOOD, 2023, 142
[24] Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS).
Garcia-Manero, Guillermo
Platzbecker, Uwe
Santini, Valeria
Zeidan, Amer Methqal
Fenaux, Pierre
Komrokji, Rami S.
Shortt, Jake
Valcarcel, David
Jonasova, Anna
Dimicoli-Salazar, Sophie
Tiong, Ing Soo
Lin, Chien-Chin
Li, Jiahui
Kreitz, Sandra
Pozharskaya, Veronika
Shetty, Jeevan K.
Degulys, Andrius
Finelli, Carlo
Cluzeau, Thomas
Della Porta, Matteo Giovanni
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Administered Daily or Weekly Times Three in Patients with Lower Risk Myelodysplastic Syndrome (MDS)
Garcia-Manero, Guillermo
Couriel, Daniel R.
Tambaro, Francesco Paolo
Gabrail, Nashat
Nadeem, Ahmed
Kadia, Tapan
Jabbour, Elias
Borthakur, Gautam
Faderl, Stefan
Newsome, Willie
Yang, Hui
Chen, Kevin
Stein, Karen
Kantarjian, Hagop
BLOOD, 2009, 114 (22) : 54 - 54
[26] The ELEMENT-MDS Trial: A Phase 3 Randomized Study Evaluating Luspatercept Versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naive, Non-Transfusion-Dependent, Lower-Risk Myelodysplastic Syndromes
Zeidan, Amer M.
Komrokji, Rami S.
Buckstein, Rena
Santini, Valeria
Rose, Shelonitda
Malini, Priya
Lew, Glen
Aggarwal, Dimple
Keeperman, Karen L.
Jiang, Huijing
Giuseppi, Ana Carolina
Zhang, Jennie
Cluzeau, Thomas
Shortt, Jake
Platzbecker, Uwe
BLOOD, 2023, 142
[27] Initial Results of a Phase I/II Study of Venetoclax in Combination with Azacitidine in Treatment-Naive and Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)
Morita, Kiyomi
Naqvi, Kiran
Montalban, Guillermo
Thompson, Philip A.
Takahashi, Koichi
Alvarado, Yesid
Jabbour, Elias
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[28] Assessment of two doses of infliximab in patients with low/intermediate risk IPSS myelodysplastic syndrome (MDS): An EORTC leukemia group (LG) randomized phase II trial (06023)
Baila, Liliana
Suciu, Stefan
Muus, Petra
Amadori, Sergio
Delforge, Michel
Ossenkoppele, Gert
Selleslag, Dominik L. D.
Thyss, Antoine
Demuynk, Hilde
Gadisseur, Alain
Vermeulen, P.
De Boer, Carla
Zwierzina, Heinz
De Witte, T. M.
BLOOD, 2007, 110 (11) : 436A - 436A
[29] Pevonedistat (PEV) plus Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 2030% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954)
Sekeres, Mikkael A.
Girshova, Larisa
Doroni, Vadim A.
Diez-Campelo, Maria
Valcarcel, David
Kambhampati, Suman
Viniou, Nora-Athina
Woszczyk, Dariusz
De Paz Arias, Raquel
Symeonidis, Argiris
Anagnostopoulos, Achilles
Munhoz, Eduardo Ciliao
Platzbecker, Uwe
Santini, Valeria
Fram, Robert J.
Yuan, Ying
Faller, Douglas V.
Ades, Lionel
BLOOD, 2021, 138
[30] Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)
Braun, Thorsten
Raffoux, Emmanuel
Prebet, Thomas
Brechignac, Sabine
Stamatoullas, Aspasia
Dreyfus, Francois
Hebibi, Zehaira
Ades, Lionel
Vey, Norbert
Dombret, Herve
Fenaux, Pierre
Cardin, Claude
BLOOD, 2011, 118 (21) : 279 - 280

← 1 2 3 4 5 →